Careers  |  Sign In  |  Register

Latest in Neurology & Neurosurgery

Two components in patient's blood may help predict the severity of disease in those with amyotrphic lateral sclerosis (ALS), also called Lou Gehrig’s disease, a CBSNews article reports. Since the average survival of ALS patients is only 1-3 years after diagnosis, clinical trials for treatment run into...
Women who use alternative nicotine products such as nicotine patches during pregnancy may be contributing to an increased risk for ADHD in their newborn child,  a Reuters article reports.  A study published in Pediatrics looked at 80,000 children born over a six-year period, noting that when compared to...

Neil Warma on Targeted Treatment for Multiple Sclerosis: Part 4

Can Tcelna’s Technology Be a Platform to Target Other Autoimmune Diseases?

Neil K. Warma, President & CEO, Opexa Therapeutics, discusses how Opexa's research into the first personalized therapy for patients with multiple sclerosis (MS) could have much broader applications as a platform technology. The technology from Opexa's drug, Tcelna, which targets specific identified...